The aim of this study is to evaluate the progression‐free survival (PFS) of recurrent ovarian cancer (ROC) patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Click to show full abstract
The aim of this study is to evaluate the progression‐free survival (PFS) of recurrent ovarian cancer (ROC) patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).
               
Click one of the above tabs to view related content.